Literature DB >> 8828942

Immunoglobulins and the regulation of autoimmunity through the immune network.

S Lacroix-Desmazes1, L Mouthon, S H Spalter, S Kaveri, M D Kazatchkine.   

Abstract

Beneficial effects of the administration of intravenous immunoglobulins (IVIg) have now been reported in a large number of autoimmune diseases, whether mediated by autoantibodies or by autoaggressive T cells. We have proposed that the immunoregulatory effect of IVIg in autoimmune disease is dependent on the selection of the recipient's immune repertoires by the variable (V) region reactivities of infused immunoglobulins. Thus IVIg contains antibodies reactive with idiotypes of natural and disease-related autoantibodies and surface immunoglobulins of B cells; IVIg also contains antibodies reactive with the idiotype, framework and constant regions of the beta chain of the alpha beta T cell receptor. Infusion of IVIg results in transient or long lasting suppression of specific autoantibody clones in vivo and in stimulation of a distinct subset of B cells reactive with the F(ab')2 fragments of IVIg Infusion of IVIg alters the general "architecture" of the network as assessed by studying the kinetic patterns of spontaneous fluctuations of natural autoantibodies in serum. Infusion of normal mouse Ig in healthy adult mice selects expressed immune repertoire by removing late pre-B and B cells in the bone marrow, mostly those expressing D proximal Vh genes, and by activating distinct subsets of B cells and CD4+ T cells in the spleen. Although dependent on the V region reactivities (composition) or injected preparations, these effects probably also require that the infused immunoglobulin contains an intact Fc moiety. If one considers the effect of IVIg on the structure, function and dynamics of the immune network IVIg may be viewed as a substitutive therapy for the quantitative/qualitative defects in network regulation that are associated with autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8828942

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

Authors:  S Y Patel; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

Review 2.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

3.  Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression.

Authors:  I Krause; M Blank; Y Levi; T Koike; V Barak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

4.  IVIG-bound IgG and IgM cloned by phage display from a healthy individual reveal the same restricted germ-line gene origin as in autoimmune thrombocytopenia.

Authors:  M Hoffmann; M M Uttenreuther-Fischer; H Lerch; G Gaedicke; P Fischer
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

5.  High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response.

Authors:  A Winder; Y Shoenfeld; R Hochman; G Keren; Y Levy; A Eldor
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

Review 6.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

Review 7.  Osteoclasts and CD8 T cells form a negative feedback loop that contributes to homeostasis of both the skeletal and immune systems.

Authors:  Zachary S Buchwald; Rajeev Aurora
Journal:  Clin Dev Immunol       Date:  2013-06-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.